Lexaria Bioscience Corp.
156 Valleyview Road
About Lexaria Bioscience Corp.Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company's technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
CEO: Chris Bunka
FOLLOW LEXARIA BIOSCIENCE:
Tweets by Lexaria Bioscience
86 articles about Lexaria Bioscience Corp.
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com
Lexaria Bioscience Corp (LXRP:OTCQX LXX:CSE), based in Kelowna, BC, focused on the improved delivery of active pharmaceutical ingredients in food, beverages and topicals, today announced that Chris Bunka, CEO will present live at VirtualInvestorConferences.com on July 11th.
Lexaria Bioscience Receives Groundbreaking U.S. Patent Allowance for Its DehydraTECHTM Delivery of THC, NSAIDs, Nicotine and Vitamins.
This Notice of Allowance applies to the delivery of all active pharmacological ingredients (“APIs”) Lexaria had been seeking.